Alyssa Mariah Sanchez

Dr. Alyssa Mariah Sanchez

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2025 in Methodist DeBakey Cardiovascular Journal
Verified
Journal Article
Open access
PDF file
NMNikitha M. Murthy
Nikitha M. Murthy
TYThomas T. Yoo
Thomas T. Yoo
ASAlyssa Mariah Sanchez
Alyssa Mariah Sanchez
MCMayur Chhitu
Mayur Chhitu
DADmitry Abramov
Dmitry Abramov
PPPurvi Parwani
Purvi Parwani
Despite medical advances and increased perioperative testing, mortality and cardiovascular complications of noncardiac surgery (NCS) have hardly declined since the early 2000s. Studies demonstrate a disproportionate overutilization of preoperative diagnostic testing with a concurrent underutilization of interventions that have been shown to meaningfully modify mortality. Consequently, there has been a paradigm shift in the approach to perioperative testing. Current thinking advocates for a more judicious and individualized approach—that is, reserving noninvasive testing for select cases at highest risk of periprocedural cardiovascular events, where it may more effectively alter management. Thus, this review provides an update of the latest evidence-based recommendations on preoperative diagnostic assessment of patients with cardiovascular risk factors undergoing NCS, proposes a framework that can be referenced when approaching such a patient in clinical practice, and highlights areas that need more data to guide decision-making in clinical practice.

3 October 2026 in American Journal of Preventive Cardiology
Verified
Journal Article
Open access
TYThomas T. Yoo
Thomas T. Yoo
ASAlyssa Mariah Sanchez
Alyssa Mariah Sanchez
EAEsteban Arevalo
Esteban Arevalo
BCBruce Adrian Casipit
Bruce Adrian Casipit
AMAbdul Mannan Khan Minhas
Abdul Mannan Khan Minhas
DADmitry Abramov
Dmitry Abramov

22 June 2026 in Kidney Medicine
Verified
Journal Article
Open access
ASAlyssa Mariah Sanchez
Alyssa Mariah Sanchez
NMNikitha Murthy
Nikitha Murthy
TYThomas Yoo
Thomas Yoo
RMRoy O. Mathew
Roy O. Mathew
SNSayna Norouzi
Sayna Norouzi
DADmitry Abramov
Dmitry Abramov

25 October 2026 in Medicina
Verified
Journal Article
Open access
PDF file
ASAlyssa Mariah Sanchez
Alyssa Mariah Sanchez
MHMehde Hasan
Mehde Hasan
KPKhalil Pathan
Khalil Pathan
ASAvery Stuart
Avery Stuart
PPPurvi Parwani
Purvi Parwani
Tricuspid regurgitation (TR) is a heterogeneous valvular disorder affecting an estimated 1.6 million adults in the United States, with increasing clinical relevance in the era of transcatheter intervention. Accurate etiologic classification is essential because primary, secondary, and cardiac implantable electronic device (CIED)-related TR arise through distinct mechanisms and carry different imaging, prognostic, and therapeutic implications. Contemporary multimodality imaging, including transthoracic echocardiography (TTE), three-dimensional echocardiography, transesophageal echocardiography (TEE), cardiac magnetic resonance (CMR), and cardiac computed tomography (CT), enables integrated assessment of valve anatomy, right-heart remodeling, pulmonary hemodynamics, and procedural suitability. In this narrative review, we propose a phenotype-based approach to secondary TR organized across six domains: chamber morphology, right atrial mechanics, annular geometry, leaflet morphology, right ventricular systolic function, and pulmonary hemodynamics. Integration of these domains may support assessment of atrial secondary TR (A-STR) and ventricular secondary TR (V-STR), while recognizing patients with overlapping atrial and ventricular features. Throughout, we distinguish consensus-derived phenotyping parameters from supportive prognostic associations and identify areas where evidence remains insufficient. We further discuss how multimodality imaging may inform procedural planning and intervention timing and highlight emerging echocardiographic markers, including right atrial reservoir strain, effective right ventricular ejection fraction (eRVEF), and CMR tissue characterization that warrant prospective validation for phenotyping, risk stratification, and assessment of myocardial reversibility. Together, this conceptual framework, which requires prospective validation, is intended to complement severity-based classification with a mechanism-informed approach to TR diagnosis and management.

29 July 2026 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
NMNikitha Murthy
Nikitha Murthy
ASAlyssa Mariah Sanchez
Alyssa Mariah Sanchez
JRJanani Rangaswami
Janani Rangaswami
SKSadiya S. Khan
Sadiya S. Khan
RMRoy O Mathew
Roy O Mathew
Key Points: The Predicting Risk of Cardiovascular Disease EVENTs equations optimize risk prediction in the modern era of increasing cardiovascular kidney metabolic disease prevalence. Risk prediction is most helpful to intensify therapy in those with less advanced kidney disease. In those with advanced kidney disease, risk indices provide little utility beyond biomarkers alone such as eGFR and albuminuria. Background: Cardiovascular kidney metabolic syndrome is a growing public health problem and leading cause of cardiovascular mortality. We evaluated model performance of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations in a large single health system population in patients with CKD and across strata of kidney function and compared findings where applicable to those of the pooled cohort equations (PCE). Methods: Veterans with eGFR measurements were divided into three groups: eGFR ≥60, eGFR 30–59, and eGFR 15–29. We assessed the base PREVENT equations for total cardiovascular disease (CVD), atherosclerotic CVD (ASCVD), and heart failure as well as add-on equations using albuminuria. Accuracy of equations was assessed with c-index as a measure of discrimination and calibration curve slopes as a measure of calibration. Results: Overall c-index was 0.651 for PREVENT-CVD, 0.633 for PREVENT-ASCVD, and 0.673 for PREVENT-heart failure. Discrimination of PREVENT-ASCVD was modestly greater than that of PCE (0.633 versus 0.629, respectively). For all three base PREVENT equations, discrimination declined with advancing kidney disease. Overall calibration slopes for the PREVENT equations ranged from 0.78 to 1.27. PREVENT-ASCVD had superior calibration compared to PCE with a calibration slope of 1.27 and 0.53, respectively. In those with urine albumin to creatinine ratio (UACR) measurements, discrimination of UACR add-on equations improved from base equations in those with less advanced kidney disease (c-index 0.624 for PREVENT-CVD UACR versus 0.607 for PREVENT-CVD base equation in those with eGFR ≥60, and c-index 0.586 for PREVENT-CVD UACR versus 0.563 for PREVENT-CVD base equation in those with eGFR 30–59). This trend was similar for the PREVENT-ASCVD and PREVENT-heart failure UACR add-on equations. Conclusions: In a CKD population, the PREVENT equations perform best in those less advanced stages of CKD and cardiovascular kidney metabolic, presenting an opportunity to apply disease-preventing and disease-modifying therapeutics in a timely manner. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mpr/www.asn-online.org/media/podcast/CJASN/2026_10_30_CJASNOct.21.10.1030.mp3